



The Chemours Company

Second Quarter Earnings Presentation

August 6, 2015

Safe Harbor Statement

This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements as further described in the “Risk Factors” section of the information statement contained in the registration statement on Form 10 and other filings made by Chemours with the Securities and Exchange Commission. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). Such measures should not be considered as replacements of GAAP. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted EBITDA to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at investors.chemours.com

Introduction

Chemours launched as an independent company on July 1, 2015

2Q15 results reflect deteriorating TiO₂ market and currency headwinds

Five-point plan announced to transform Chemours into a higher-value chemistry company

Targeting \$140 million improvement in second half 2015 Adjusted EBITDA

New Independent board expects to announce a sustainable dividend in third quarter

2Q15 Results Overview

(\$ in millions unless otherwise noted)

Financial Summary*


	2Q15	1Q15	2Q14
Net Sales	\$1,508	\$1,363	\$1,682
Adj. EBITDA	127	145	235
<i>Adj. EBITDA Margin (%)</i>	<i>8.4</i>	<i>10.6</i>	<i>14.0</i>
Net Income	(18)	43	116
Proforma EPS	(0.10)	0.24	0.64

- Completed separation from DuPont on July 1, 2015
- Results impacted by
 - Weak TiO₂ pricing environment
 - Continued currency headwinds
- Net loss includes restructuring and interest expenses
- Adjusted EBITDA reflects stand-alone adjustments
- Restructuring actions initiated in 2Q15

*See reconciliation of Non-GAAP measures in the Appendix


Adjusted EBITDA* Bridge: 2Q14 – 2Q15

(\$ in millions)



Adjusted EBITDA* Bridge: 1Q15 – 2Q15

(\$ in millions)



Environmental Liabilities and Litigation Matters

Environmental Liabilities

Environmental Remediation

- Environmental liabilities are well understood and well managed
- Accrued liability of \$302 million as of 6/30/15
- Based on estimated remediation activities and average 15-20 year horizon
- Annual expenses reflected in Adjusted EBITDA

Notifications received for ~170 sites

- ~50% – resolved
- ~15% – no liability based on current information
- ~35% – active remediation underway

Litigation Matters

Asbestos

- Accrued liability of \$38 million at 6/30/15
- ~2,500 cases alleging personal injury from exposure at sites between ~1950 to ~1990
- Accrued liability estimated based on precedent settlement history

PFOA

- Accrued liability of \$14 million at 6/30/15 related to water treatment obligations
- Little Hocking Water Association claim
- Voluntary medical monitoring for defined population
- ~3,500 individual personal injury claims to be tried one-by-one, sequentially

Balance Sheet and Liquidity

(\$ in millions unless otherwise noted)

	6/30/15
Cash	247
Total Liquidity ¹ (Cash + Revolver)	632
Funded Debt	3,943
Net Debt (Funded Debt – Cash)	3,696
Net Debt / EBITDA ²	5.2x
Interest Coverage Ratio	3.2x


- Starting cash balance of \$247M in excess of spin-off target balance of \$200M and subject to true-up under Separation Agreement
- Total Liquidity of \$632M, reflects revolver availability of \$385M¹
- Anticipate favorable working capital unwind through year end
- Full-year capital expenditures, excluding separation-related items, expected to be \$400M - \$450M
- Starting Net Debt/EBITDA of 5.2x demonstrates the need to focus on de-levering

¹ Calculation based on compliance EBITDA

² Based on LTM EBITDA of \$712 million, compliance EBITDA may vary

2H 2015 Adjusted EBITDA Improvements

(\$ in millions)



Targeting \$140M Adjusted EBITDA Improvement in Second Half 2015

Chemours Transformation Plan

Transformation Plan Priorities

Reduce Costs

- \$2.4B starting cost position* includes SG&A, R&D and plant fixed costs
- \$200M cost reductions in 2016; including \$40M from actions taken in second quarter 2015
- Target a total of \$350M of structural reductions in 2017

Optimize The Portfolio

- Evaluate strategic alternatives for Chemical Solutions portfolio, excluding Cyanides

Grow Market Positions

- Support customer growth in TiO₂ through successful Altamira start-up
- Continue ramp up of Opteon™ product line in Fluoroproducts
- Grow Cyanides business within Chemical Solutions

Refocus Investments

- Concentrate capital spending on investable business portfolio
- Invest in the next increment of Opteon™ and Cyanides capacity
- Rationalize annual capital spending to ~\$350M in 2017

Enhance Our Organization

- Foster an entrepreneurial organization
- Operate with a simpler structure
- Maintain a commitment to a safe and sustainable future

Enhance Adjusted EBITDA by \$500M and Improve Leverage Position to ~3x in 2017

*Twelve months ending 6/30/15




Chemours™

\$M represents millions, \$B represents billions


Actions to Further Enhance Profitability in 2017

(\$ in millions)



\$500M in Incremental EBITDA over 2015

Multiple Factors to Achieve Target Leverage



Approximately 3x Net Debt / Adjusted EBITDA in 2017

Chemours Transformation Plan: Summary





Chemours™

Appendix

Environmental Liabilities and Litigation Matters

Environmental Liabilities

Environmental expenses

- Environmental operating costs and increases in remediation accrual
- Reflected in Adjusted EBITDA

Notifications received for ~170 sites

- ~15% – no liability based on current information
- ~35% – active remediation underway
- ~50% – resolved

Accrued liability of \$302 million as of 6/30/15

- Based on estimated remediation activities and average 15-20 year horizon
- Potential range up to additional \$650 million – contingent on extension of time or activities required to treat known sites

Pompton Lakes

- Accrued liability of \$86 million as of 6/30/15 included within the environmental reserve notes above of \$302 million
- Remediation efforts to start in 3Q15
- Expected additional cash outflow over next 2-3 years of \$50 million total

Expected Environmental Remediation Payments*

2015	2016	2017
\$52	\$55	\$55

* Estimates as of 6/30/15

Litigation Matters

Asbestos

- Accrued liability of \$38 million at 6/30/15
- ~2,500 cases alleging personal injury from exposure at sites between ~1950 to ~1990
- Accrued liability estimated based on precedent settlement history

PFOA

- Accrued liability of \$14 million at 6/30/15
- Related to water treatment obligations

Additional PFOA Matters

1. Provide medical monitoring for defined population
 - No accrued liability at this time
 - Voluntary participation with the defined population
 - \$1 million funded in January 2012; capped at \$235 million
2. ~3,500 individual personal injury claims
 - Related to 6 disease types; majority related to high cholesterol and thyroid disease
 - First two trials set to begin in September and November with four additional trials in 2016
 - Range of possible exposure cannot be estimated at this time
3. Little Hocking Water Association
 - Local water authority seeking monetary damages and injunctive relief
 - Trial set to begin October 2015; no liability accrued at this time

(\$ in millions unless otherwise noted)

Adjusted EBITDA to Net (Loss) Income Reconciliation

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2015	2014	2015	2014
Total segment Adjusted EBITDA	\$127	\$235	\$272	\$436
Interest	(28)	-	(28)	-
Depreciation and amortization	(67)	(64)	(131)	(128)
Non-operating pension and other postretirement employee benefit costs	(8)	(10)	(15)	(15)
Exchange gains	19	5	3	4
Restructuring charges	(61)	(20)	(61)	(21)
Gains on sale of business or assets	-	9	-	11
(Loss) income before income taxes	(18)	155	40	287
Provision for income taxes	-	39	15	73
Net (loss) income	(\$18)	\$116	\$25	\$214



Chemours™